Reported outcomes in phase II studies of newly-diagnosed pulmonary tuberculosis

Abstract

Background Tuberculosis (TB) remains a major killer amongst infectious diseases. Current treatment involves a four-drug regimen for at least six months. New drugs and regimens are required to shorten treatment duration, reduce toxicity and combat drug resistance however the optimal methodology to define the critical path for these regimens is not well-defined. We undertook a literature review to summarise outcomes reported in phase II trials of patients with newlydiagnosed pulmonary TB to determine the necessity for a core outcome set in TB.